Spinal Cord Stimulation Market and Globus’ Acquisition of Nevro

The spinal cord stimulation (SCS) market is undergoing a significant transformation, driven by technological advancements and an increasing demand for non-pharmacological solutions to chronic pain. With rising concerns about opioid use and side effects, the adoption of spinal cord stimulation devices has surged as a safer, drug-free alternative. This shift is exemplified by recent industry developments, including Globus Medical’s acquisition of Nevro, a company specializing in neuromodulation solutions. This deal, valued at approximately $250 million, marks an important move by Globus to expand into the growing neuromodulation space, particularly in the SCS market.

This article explores the factors driving the growth of the spinal cord stimulation market, the key players shaping its future, and the technological innovations that are poised to redefine the way chronic pain is managed.

A Deep Dive into the Spinal Cord Stimulation Market

Why Spinal Cord Stimulation?

Chronic pain continues to be one of the most challenging health issues worldwide. It affects approximately 20% of adults globally, with an even higher incidence in the United States, where 24% of adults suffer from chronic pain. For years, spinal cord stimulation has served as an effective treatment option for patients who have not found relief through conventional therapies. By delivering electrical impulses to the spinal cord, SCS devices help mask pain signals before they reach the brain.

The adoption of SCS technology has grown steadily due to its ability to offer long-term relief without relying on medications. With chronic pain affecting millions, the spinal cord stimulation market is seeing accelerated innovation, resulting in more effective and accessible solutions for patients.

Market Growth and Key Figures

In 2024, the spinal cord stimulation market was valued at approximately $2.5 billion, accounting for a significant portion of the $6 billion global neuromodulation devices market. This segment is poised for steady growth, projected to expand at a compound annual growth rate (CAGR) of 4.4% between 2024 and 2029. The United States alone accounted for approximately 57,000 SCS implant procedures in 2024, with the number expected to rise steadily in the coming years as more patients turn to SCS for pain management.

Despite this growth, the market remains under-penetrated, with a large portion of patients still relying on traditional pain management methods. However, as clinical evidence supporting SCS becomes more robust, its adoption is likely to increase, positioning it as a frontline option for managing chronic pain.

Drivers of Growth in Spinal Cord Stimulation

There are several key factors driving the rapid expansion of the spinal cord stimulation market, as detailed below.

Globus Medical’s Acquisition of Nevro

On February 6, 2025, Globus Medical announced its plans to acquire Nevro, a leading provider of neuromodulation solutions. This $250 million deal highlights the growing importance of the spinal cord stimulation market and the expanding interest in neuromodulation as a whole. Nevro’s products, including the Senza and HFX systems, represent a significant portion of the market, with Nevro capturing approximately 16.4% of the global SCS market.

Globus Medical is a leader in musculoskeletal products, and this acquisition will enable the company to expand into the rapidly growing neuromodulation space. Globus has indicated that its strong commercial and operational capabilities will accelerate the adoption of Nevro’s technology, driving faster market penetration. This strategic move is expected to strengthen Globus’s position in the spine devices market and further enhance its competitive edge.

Innovation and Technology: Key Players to Watch

As the spinal cord stimulation market continues to grow, several companies are leading the charge in terms of innovation. Some of the key players to watch include:

• Medtronic: The dominant player in the SCS space, Medtronic continues to innovate with advanced stimulation technologies and cutting-edge devices that are shaping the future of pain management.
• Boston Scientific: Known for its deep expertise in medical devices, Boston Scientific is heavily invested in expanding its neuromodulation portfolio, with a focus on delivering more effective SCS solutions.
• Abbott: Abbott’s neuromodulation division is making strides in the SCS market, focusing on delivering more patient-centric solutions that enhance comfort and long-term outcomes.
• Saluda Medical: A growing player in the SCS space, Saluda Medical is pioneering the development of closed-loop systems that allow for real-time adjustments to nerve signals, improving efficacy and reducing side effects.

Emerging companies like WISE SpA and Nalu Medical are also making waves in the SCS market with new technologies that could disrupt the status quo.

The Future of the Spinal Cord Stimulation Market

As the spinal cord stimulation market evolves, several trends are expected to shape its future:

1. Increased Market Penetration: With growing clinical evidence supporting the efficacy of SCS, its adoption is expected to increase, especially as more patients seek opioid-free pain management solutions.
2. Continued Innovation: Advances in SCS technology will lead to more effective and personalized treatments. Technologies like closed-loop stimulation, real-time feedback, and improvements in lead design are making SCS more precise and adaptable to patient needs.
3. Broader Indications: As research expands into new therapeutic areas, the potential applications for SCS are increasing, which could open up new markets and expand the patient base significantly.
4. Partnerships and Acquisitions: Strategic acquisitions, like Globus Medical’s purchase of Nevro, are likely to continue as larger players seek to strengthen their positions in the competitive SCS market. These partnerships will drive innovation, improve technology adoption, and open new opportunities for market expansion.

Conclusion: The Outlook for the Spinal Cord Stimulation Market

The spinal cord stimulation market is positioned for significant growth as advancements in technology and a rising demand for non-opioid pain management solutions drive adoption. The recent acquisition of Nevro by Globus Medical underscores the growing importance of neuromodulation and its potential to reshape pain management. As more companies innovate and expand their offerings, the future of the spinal cord stimulation market looks promising, with opportunities for both established players and emerging companies to capture market share.

With the rising global burden of chronic pain, SCS will continue to play a pivotal role in providing lasting relief for millions of patients, making it a key market to watch in the years ahead.

Stay Ahead with LSI Market Intelligence

Gain access to the latest data and insights driving the medtech industry. Explore our Global Procedure Volumes Database to stay informed on key market trends and make data-driven decisions.

Looking to connect with key industry leaders? Join us for our upcoming medtech conference in Dana Point this March.